Delving into the Latest Updates on Phenazopyridine Hydrochloride with Synapse

Overview

Basic Info

SummaryPhenazopyridine, a diminutive molecule, serves primarily as an analgesic agent for urinary tract pain. Its mode of action involves alleviating the discomfort associated with urinary tract infections, bladder inflammation, and other related maladies. The inception of phenazopyridine's use dates back to 1928 and, since then, it has burgeoned into a popular choice for individuals experiencing arduous urination or other urinary tract symptoms. It is crucial to note, however, that while phenazopyridine effectively mitigates pain, it does not remedy the underlying condition that engenders the discomfort. Thus, healthcare professionals must supervise phenazopyridine use as it may interact adversely with other medications and engender potential side effects.

Drug Type

Small molecule drug

Synonyms

2,6-Diamino-3-(phenylazo)pyridine, 2,6-Diamino-3-phenylazopyridine, 3-(Phenylazo)-2,6-pyridinediamine

+ [7]

Target-

Action-

Mechanism-

Therapeutic Areas

Nervous System DiseasesInfectious DiseasesOther Diseases

Active Indication

PainShock, Septic

Inactive Indication

BurnsDysuriaUrinary Incontinence+ [1]

Originator Organization-

Active Organization

University of Western OntarioKaren Pharmaceutical Co. Ltd.

Inactive Organization

Amneal Intermediate, Inc.

Pro Doc LtéeLaboratórios Osório de Moraes Ltda

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (01 Jan 1928)

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC11H12ClN5

InChIKeyQQBPIHBUCMDKFG-UHFFFAOYSA-N

CAS Registry136-40-3

View All Structures (2)

The goal of this clinical trial is to learn more about using phenazopyridine (Pyridium) for pain control during bladder onabotulinumtoxinA ("botox") injections for surgical management of overactive bladder (OAB) for patients at Montefiore Medical Center in The Bronx. It will also learn about if using the phenazopyridine pill affects how satisfied patients are with their experience, how much pain patients feel afterwards, and if doctors think using the Pyridium pill affected how they performed the procedure. The main question it aims to answer is:
- Is oral phenazopyridine at least as good as intravesical lidocaine is for managing pain with bladder botox injections for OAB in Montefiore patients?
Researchers will compare phenazopyridine to intravesical lidocaine, a liquid put into the bladder, to see if phenazopyridine is at least as good at controlling pain with bladder botox injections as intravesical lidocaine is.
Participants will be assigned, by chance, to receive either the oral phenazopyridine pill or the intravesical lidocaine as their pain control for the procedure.

Start Date01 May 2025

Sponsor / Collaborator

Montefiore Medical Center

NCT06577493

/ RecruitingPhase 4IIT

Effectiveness of Phenazopyridine for Pain Following Urodynamics

The purpose of the study is to determine if taking phenazopyridine (AZO) at the time of urodynamic study testing will decrease pain experienced by patients after undergoing urodynamic testing.

Start Date17 Dec 2024

Sponsor / Collaborator

University of South Florida

CTRI/2024/06/068294

/ Not yet recruitingPhase 3

A Randomized Double blinded Placebo controlled study to evaluate the efficacy of Phenazopyridine with Nitrofurantoin in patients with Urinary tract infection - NIL

Start Date15 Jun 2024

Sponsor / Collaborator-

100 Clinical Results associated with Phenazopyridine Hydrochloride

Login to view more data

100 Translational Medicine associated with Phenazopyridine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Phenazopyridine Hydrochloride

Login to view more data

789

Literatures (Medical) associated with Phenazopyridine Hydrochloride

01 Dec 2025·Current Urology Reports

Management of Lower Urinary Tract Symptoms during the Treatment for Non-Muscle Invasive Bladder Cancer

Review

Author: Seiden, Benjamin ; Ajay, Divya ; Pietzak, Eugene ; Clements, Matthew ; Cheung, Felix

PURPOSE OF REVIEWThis narrative review aims to report upon the existing treatment evidence and strategies for managing lower urinary tract symptoms (LUTS) during treatment, including transurethral resection and intravesical therapy. This review also attempts to examine novel approaches to mitigate treatment-related lower urinary tract symptoms and improve treatment adherence.RECENT FINDINGSThere is sparse but promising evidence in improving LUTS secondary to intravesical therapy. Oral agents including phenazopyridine and hyaluronic acid, Bacillus Calmette-Guerin dose reduction, and emerging therapies including beta-3 agonists as well as Onabotulinumtoxin A injections all have demonstrated encouraging improvement in LUTS in limited research. Although recent literature explores new medications and potential strategies for managing intravesical therapy-related LUTS, further research is required to establish efficacy and new consensus on treatment strategies. Further research is also required to establish effective LUTS mitigation strategies with other emerging intravesical therapy regimens.

01 Apr 2025·European Journal of Medicinal Chemistry

Discovery and optimization of phenazopyridine hydrochloride as novel SARS-CoV-2 RdRp inhibitors

Article

Author: Liu, Tianfu ; Wang, Yujia ; Li, Quanjie ; Yi, Dongrong ; Li, Xiaoyu ; Guo, Saisai ; Zhang, Guoning ; Tan, Wenjie ; Cen, Shan ; Wang, Yucheng ; Zhao, Jianyuan ; Li, YaSheng ; Ma, Ling ; Li, Jiabin ; Shi, Yu

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the pathogen of coronavirus disease (COVID-19) causing a pandemic with growing global transmission. The viral RNA-dependent RNA polymerase (RdRp) is conserved especially for variants of concern (VOCs), making it as an effective antivirals target. Due to the proofreading activity of coronavirus nsp14/nsp10, limited the efficacy of nucleoside analogs in vivo. Herein, we identified that Phenazopyridine hydrochloride (PAP) inhibits SARS-CoV-2 with EC₅₀ of 5.37 μmol/L. Furthermore, PAP can effectively inhibit SARS-CoV-2 RdRp with EC₅₀ value of 7.37 μmol/L, after further optimization, compound PAP-22 exhibits the most potential inhibition, with EC₅₀ of 1.11 μmol/L. PAP and its derivatives can bind directly to SARS-CoV-2 RdRp, fully resistance to the exoribonuclease (ExoN) and exhibit broad spectrum anti-CoV activities. Combined with the current data available on the safe and pharmacokinetics of PAP as an approved drug in clinical use, these results provide a path for the urgently needed antivirals to combat SARS-CoV-2.

01 Jan 2025·Journal of Molecular Liquids

Enhanced sonophotocatalytic degradation of phenazopyridine using mesoporous nickel oxide nanoparticles synthesized by a solvothermal method in deep eutectic solvent

Author: Zarei, Mahmoud ; Darbandi, Masih ; Najafi, At-har

NiO nano-photocatalysts have demonstrated good photocatalytic performance for the degradation of wastewater pollutants.The purpose of this study is to investigate the effect of Deep Eutectic Solvent (DES) on the structure, morphol., and photocatalytic activity of synthesized nanoparticles.Herein, mesoporous NiO nanoparticles (NPs) were synthesized in the presence of DES by a solvothermal method.The synthesized nanostructures were characterized using XRD (X-ray diffraction), BET (Brunauer-Emmett-Teller), and HRTEM/TEM (High-Resolution Transmission Electron Microscopy) to evaluate their crystallinity, size, composition, and morphol.The anal. shows that the NiO NPs synthesized in DES have high porosity and sp. surface area which results in better photocatalytic performance for the degradation of organic pollutants.NiO NPs can remove 90%, 81%, and 0% of organic model pollutant phenazopyridine (PhP) during sonophotocatalytic, photocatalytic, and sonocatalytic processes, resp.The simultaneous use of ultrasonic radiation, UV lamp, and prepared catalyst in the sonophotocatalytic reaction had a pos. synergistic effect of about 28.36%.The mechanism of the sonophotocatalytic process was studied through the addition of scavengers and enhancers.Scavengers like formic acid (14%), isopropanol (15%), and sodium bicarbonate (76%) significantly declined removal efficiency.Conversely, the presence of potassium persulfate (97%) as an enhancer improved degradation efficiency by 7%.The degradation of PhP exhibits pseudo-first-order kinetics across all experiments (R² > 0.97).The reusability test shows a negligible decline in sonophotocatalytic performance after four consecutive uses.This feature improves the application of nano-photocatalysts in the industrial field, like wastewater treatment.

100 Deals associated with Phenazopyridine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D05450	Phenazopyridine Hydrochloride	G04BX06	DB01438

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pain	China	Karen Pharmaceutical Co. Ltd.	01 Jan 2003

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Shock, Septic	Preclinical	United Kingdom	University of Western Ontario	01 Jul 2024
Urinary Incontinence	Discovery	United States	Amneal Intermediate, Inc.	01 Feb 2012
Burns	Discovery	United States	Amneal Intermediate, Inc.	01 Dec 2009
Dysuria	Discovery	-	Laboratórios Osório de Moraes Ltda	01 Dec 2009
Pain	Discovery	United States	Amneal Intermediate, Inc.	01 Dec 2009
Urinary Tract Infections	Discovery	United States	Amneal Intermediate, Inc.	01 Dec 2009

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03755089 (Pubmed \| Am J Obstet Gynecol) Manual	Phase 4	Urinary Bladder, Overactive	100	phenazopyridine	(ukfkfxkrxq): difference = -2.7 (95% CI, -11.3 to 10.7)	Negative	14 May 2022
				lidocaine
NCT02476448 (JET, CTgov)	Not Applicable	Ureteral Diseases	176	normal saline (Normal Saline)	mkssblqigl(aoozxyhpli) = ppjapfqltg cbtboocurm (soenbsnahq, nelwtbtrwf - kikentkfmx) View more	-	23 Oct 2019
				Dextrose 10% (Dextrose 10%)	mkssblqigl(aoozxyhpli) = haqghirgix cbtboocurm (soenbsnahq, erkrcbmnfz - gahlxijvzg) View more
NCT02677623 (CTgov)	Phase 4	Ureteral Obstruction	140	Pyridium (A- Pyridium)	vvwbqosdvm(czkuwgzjeb) = sbpudgiblj vpgvlhxcdx (pnjxdpgfly, sxmvqulgrp - qvdtgbsujt) View more	-	30 May 2019
				Sodium Fluorescein (B- Sodium Fluorescein)	vvwbqosdvm(czkuwgzjeb) = jdwykbwcxx vpgvlhxcdx (pnjxdpgfly, exjhbjotdi - rftvhjqnxw) View more
NCT03065075 (Pubmed \| Female Pelvic Med Reconstr Surg)	Phase 3	Visceral Prolapse	152	Phenazopyridine 200 mg	ntjggzydle(vkqfmkhynt) = kszamuevpt nianjxtbni (dzcmtvhszm )	Negative	26 Apr 2019
				No additional phenazopyridine	ntjggzydle(vkqfmkhynt) = vuokxpjepp nianjxtbni (dzcmtvhszm )
NCT03065075 (EPOV, CTgov)	Phase 3	Uterine Prolapse \| Urinary Retention	152	Phenazopyridine (Phenazopyridine)	skhzkfccxr(fndlpincgv) = ehfrebtvsu arubfbouco (jihhyhdfgm, tfcxooemjl - ztccvxjvns) View more	-	26 Mar 2019
				Phenazopyridine (No Phenazopyridine)	skhzkfccxr(fndlpincgv) = anrdfyaljb arubfbouco (jihhyhdfgm, lkedsmnxgj - lruarwalht) View more
NCT02806713 (EPIPhANy, CTgov)	Phase 3	Urologic Diseases \| Pain, Postoperative	92	no Phenazopyridine (no Phenazopyridine)	(uoiuajitzp) = copouzikul iemziexprg (kdpymxropf, vtzidcgffm - ehmytpazfp) View more	-	05 Feb 2019
				Phenazopyridine (Phenazopyridine)	(uoiuajitzp) = xiwqdrtrbq iemziexprg (kdpymxropf, rjnrsertde - ngmyvekfme) View more